Oncology Markets for IDH Inhibitors


oncology markets for IDH inhibitors  Oncology Markets for IDH Inhibitors  • April 2019  •  CDH496K •  Price US $2,850



 

Predictive biomarkers for oncology are necessary to accurately identify patients who will benefit from anticancer treatment. Recently approved oncology drugs target discrete molecular aberrations or pathways in tumor cells and consequently are active on a subset of patient population, yet clinical studies have shown that not all biomarker-positive patients respond. The advancement of predictive biomarkers needs to detect novel and evolving drug resistance mechanisms, not only to guide the selection of patient subsets for specific treatments, but to identify new therapeutic targets.

Bar_Graph  Oncology Markets for IDH Inhibitors Report Brochure (Download PDF)

Blue document  Oncology Markets for IDH Inhibitors Report Order Form (Download PDF)

 

   Order Online

 

 


What You Will Learn

  • Who are the developers and suppliers of IDH inhibitors? What are their capabilities and market strategies?
  • What is the competitive landscape for late-stage development IDH inhibitors and what indications are they targeting?
  • What is the size of the market for IDH inhibitors today, who are the market share leaders, and what will the market be in 2022?
  • How important are drug developer-device manufacturer relationships and what are the key alliances in the industry?
  • What are the significant economic, technology, and regulatory factors affecting the market for biomarker-based oncology therapeutics?

Oncology Markets for IDH Inhibitors – Summary of Contents

 

The Opportunity
Mutated IDH
Mutated IDH – Mechanisms of Action
IDH Inhibitor Therapeutics
Inhibition of IDH
FDA-Approved IDH Inhibitors
Development-stage Drugs
Competing Therapies
INDICATIONS
Acute Myeloid Leukemia
Competing Drugs Prescribed for Treating AML
FLT3 inhibitors
Gemtuzumab ozogamicin (Mylotarg)
Venetoclax (Venclexta)
Hedgehog pathway inhibitor
Cholangiocarcinoma
Glioma
IDH TESTING
Non-small Cell Lung Cancer
Market Factors
Standards Organizations
Pharmaceutical Insurance Coverage & Managed Care
Company Profiles
AGIOS
Aslan Pharmaceuticals
Bayer
Beigene
Bristol-Myers Squibb
Celgene
Daiichi Sankyo
Philogen S.p.A.
Tesaro
Tragara/Adastra
Tocagen